Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing ...

CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Gearing Up for Phase 3 Trial of Tecarfarin Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is a biopharmaceutical company developing tecarfarin, a ...

In the RIVAWAR trial, patients hospitalized for a heart attack who were treated with rivaroxaban for left ventricular ...

In the rarest of rare cases and a groundbreaking medical achievement, Medica Superspecialty Hospital in Kolkata achieved a momentous feat by successfully implanting a Micra leadless pacemaker in a ...

Cardiac Dimensions, a Kirkland, Wash., company with a technology to treat heart valve malfunction, has raised $53 million ...

Cardiac Dimensions has secured $53m in a Series E funding round to support its ongoing pivotal trial assessing the company’s ...

A novel therapeutic showed significant promise in slowing aortic valve calcification, potentially extending time until or eliminating need for transcatheter or surgical intervention for stenosis, ...

Longer-term treatment with aficamten resulted in statistically significant improvements (mean ±SD) in measures of cardiac structure and function including left ventricular mass index (-9.8 g/m2 ±18.1, ...

According to doctors, the condition can lead to the thickening of your heart muscle, left ventricular stiffness, mitral valve changes, and cellular changes, all of which can be life-threatening.

a condition that affects the mitral valve, which controls blood flow between the heart’s left atrium and left ventricle. When this valve doesn’t function properly, it can lead to serious heart ...